PT1175489E - Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas - Google Patents

Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas

Info

Publication number
PT1175489E
PT1175489E PT00910916T PT00910916T PT1175489E PT 1175489 E PT1175489 E PT 1175489E PT 00910916 T PT00910916 T PT 00910916T PT 00910916 T PT00910916 T PT 00910916T PT 1175489 E PT1175489 E PT 1175489E
Authority
PT
Portugal
Prior art keywords
secondary structure
antisense sequence
oligonucleotide
pharmaceutical compositions
same
Prior art date
Application number
PT00910916T
Other languages
English (en)
Inventor
Malvy Claude
Maksimenko Andrei
Helin Valerie
Gottikh Marina
Original Assignee
Inst Gustave Roussy Igr
Centre Nat Rech Scient
Bioalliance Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Gustave Roussy Igr, Centre Nat Rech Scient, Bioalliance Pharma Sa filed Critical Inst Gustave Roussy Igr
Publication of PT1175489E publication Critical patent/PT1175489E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PT00910916T 1999-03-09 2000-03-09 Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas PT1175489E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9902921A FR2790757B1 (fr) 1999-03-09 1999-03-09 Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.

Publications (1)

Publication Number Publication Date
PT1175489E true PT1175489E (pt) 2006-10-31

Family

ID=9542992

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00910916T PT1175489E (pt) 1999-03-09 2000-03-09 Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas

Country Status (12)

Country Link
US (1) US7022832B2 (pt)
EP (1) EP1175489B1 (pt)
JP (1) JP2004500018A (pt)
AT (1) ATE328074T1 (pt)
AU (1) AU3295700A (pt)
CA (1) CA2363255A1 (pt)
DE (1) DE60028367T2 (pt)
DK (1) DK1175489T3 (pt)
ES (1) ES2265916T3 (pt)
FR (1) FR2790757B1 (pt)
PT (1) PT1175489E (pt)
WO (1) WO2000053745A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040022449A (ko) 2001-07-12 2004-03-12 유니버시티 오브 매사추세츠 유전자 불활성화를 매개하는 소형 간섭 ｒｎａ의 생체내제조
WO2006074108A2 (en) * 2004-12-30 2006-07-13 Hauser Todd M Compositions and methods for modulating gene expression using self-protected oligonucleotides
WO2007043049A1 (en) * 2005-10-11 2007-04-19 Ben-Gurion University Of The Negev Research And Development Authority Compositions for silencing the expression of vdac1 and uses thereof
US20100144831A1 (en) * 2006-09-27 2010-06-10 Habib Fakhral Blocking of gene expression in eukaryotic cells
US7645578B2 (en) * 2006-10-31 2010-01-12 Agilent Technologies, Inc. Cleavage of RNA at redundant sites
ATE508191T1 (de) 2006-11-01 2011-05-15 Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase
US8283460B2 (en) 2008-10-15 2012-10-09 Somagenics, Inc. Short hairpin RNAs for inhibition of gene expression
EP2363467B1 (en) * 2008-10-23 2015-12-16 The University of Tokyo Method for inhibiting function of micro-rna
US8871730B2 (en) 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
EP2933333B1 (en) * 2010-07-08 2018-02-21 Bonac Corporation Single-strand nucleic acid molecule for controlling gene expression
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
US20160040163A1 (en) * 2013-03-15 2016-02-11 Pronai Therapeutics, Inc. Dnai for the modulation of genes
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
KR102357337B1 (ko) 2013-12-27 2022-01-28 가부시키가이샤 보낙 유전자 발현 제어를 위한 인공 매치형 miRNA 및 그 용도
ES2872527T3 (es) 2014-12-27 2021-11-02 Bonac Corp miARN natural para controlar la expresión génica y uso del mismo
ES2926369T3 (es) 2015-03-27 2022-10-25 Bonac Corp Molécula de ácido nucleico monocatenario que tiene función de suministro y capacidad de control de la expresión génica

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501928A (ja) * 1992-07-02 1996-03-05 ハイブライドン インコーポレイテッド 治療剤としての自己安定化オリゴヌクレオチド
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5631148A (en) * 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement

Also Published As

Publication number Publication date
DE60028367D1 (de) 2006-07-06
US20020156261A1 (en) 2002-10-24
WO2000053745A9 (fr) 2001-11-08
ATE328074T1 (de) 2006-06-15
EP1175489A1 (fr) 2002-01-30
CA2363255A1 (fr) 2000-09-14
EP1175489B1 (fr) 2006-05-31
FR2790757B1 (fr) 2003-08-01
DK1175489T3 (da) 2006-10-02
JP2004500018A (ja) 2004-01-08
ES2265916T3 (es) 2007-03-01
FR2790757A1 (fr) 2000-09-15
DE60028367T2 (de) 2007-02-08
AU3295700A (en) 2000-09-28
WO2000053745A1 (fr) 2000-09-14
US7022832B2 (en) 2006-04-04

Similar Documents

Publication Publication Date Title
PT1175489E (pt) Oligonucleotidos contendo uma sequencia antisense estabilizada por uma estrutura secundaria e composicoes farmaceuticas contendo as mesmas
EP1798285B1 (de) Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
IL166546A (en) Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
MX2008014100A (es) Compuestos y metodos para modular la expresion de pcsk9.
ATE416183T1 (de) Oligonukleotide mit alternierenden segmenten und deren verwendungen
ATE479752T1 (de) Therapeutische zusammensetzungen
DK0731835T3 (da) Antisense-oligonukleotider med tumorigenicitetshæmmende virkning
WO2007056326A3 (en) Compositions and methods for inhibiting expression of nav1.8 gene
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
WO2003101394A3 (en) Defensins: use as antiviral agents
HK1159988A1 (en) Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2005039480A3 (en) AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
IL164674A (en) Catalytic deoxyribonucleic acid that cleaves pai-1 and uses thereof
DK1537210T3 (da) Decoy-oligonukleotid-inhibering af CD40-ekspression
EP2527442A3 (en) Compounds and methods for modulating gene expression
NZ741086B2 (en) Compositions and methods for inhibiting gene expression of lpa
WO2004035759A3 (en) Inhibitory oligonucleotides targeted to matrix metalloproteinase-9